

EP-064 - CORRELATION BETWEEN PHYSICIAN AND PATIENT DISEASE ASSESSMENTS IN ULCERATIVE COLITIS: BASELINE DATA FROM THE ICONIC STUDY OF 1816 PATIENTS IN 33 COUNTRIES

S. Ghosh⁶; L. Peyrin-Biroulet¹; T. Sensky²; F. Casellas³; C. O'shea⁴; B Pappalardo⁵

1 - University of Lorraine, Nancy, France; 2 - Imperial College, London, United Kingdom; 3 - Crohn-Colitis Care Unit (UACC), Hospital Universitari Vall d'Hebron, Barcelona, Spain,; 4 - AbbVie Ltd, Dublin, Ireland; 5 - AbbVie Inc., North Chicago, IL, United States; 6 - University of Birmingham, Birmingham, United Kingdom

Background: ICONIC is the largest prospective multi-country (n=33) observational study, assessing burden in adult ulcerative colitis (UC) patients (pts) under routine care. Both pt & physician assessments of disease severity, activity & life impact will be captured at 6 month intervals through 2 yrs. This analysis will evaluate baseline (BL) demographics, clinical characteristics & the extent of agreement between pts & physicians in measures of disease activity.

Methods: Adult pts with early UC (diagnosed ≤36 months) were enrolled irrespective of disease severity or treatment. Pt self-assessments include: disease severity, Pictorial Representation of Illness & Self-Measure (PRISM, [a tool assessing perception of disease-associated suffering]), Patient Health Questionnaire-9 (PHQ-9), Short Inflammatory Bowel Disease Questionnaire (SIBDQ) & pt-modified Simple Clinical Colitis Activity Index (P-SCCAI). Physician assessments include: clinical parameters, PRISM, & SCCAI. Correlation between PRISM & SIBDQ, PHQ-9, & SCCAI were evaluated. BL characteristics were obtained from observed data by calculating means. Mean differences between pt & physican measures were calculated using a one-sample t-test. Correlation analyses were performed by kappa statistics & Pearson correlation.

Table 1. Baseline clinical & demographic characteristics of UC patients in ICONIC*

Table 1. Baseline clinical & demographic characteristics	•
Characteristic	All patients N=1816
Sex, n (%)	833 (45.9)
Female	000 (1010)
Age, years	
Mean ± SD	38.5 ± 14.6
Current smoker, n (%)	212 (11.7)
Time since UC diagnosis, days	
Median (25% 0, 75% Q)	171 (59, 317)
Disease Duration, n (%)	
0 - 6 months	873 (48.1)
6 months - 1 year	584 (32.2)
1-3 years	278 (15.3)
Duration of symptoms prior to UC diagnosis, n (%) < 1 year	
1-3 years	1296 (71.4)
> 3 years	380 (20.9)
	134 (7.4)
Disease severity since diagnosis, n (%)	
Improved	1278 (70.4)
Worsened (flare)	157 (8.6)
Remains similar	330 (18.2)
Endoscopic finding, n (%)	
Normal/Inactive	93 (5.1)
Mild	390 (21.5)
Moderate	550 (30.3)
Severe	209 (11.5)
Physician assessment of UC severity, n%	
Mild	672 (37.0)
Moderate	668 (36.8)
Severe	234 (12.9)
In remission	230 (12.7)
SI BDQ	
Mean ± SD	48.4 ± 13.2
PHQ-9	
Mean ± SD	6.3 ± 5.4
PHQ-9 depression severity, n (%)	









Mild 556 (30.6) Moderate 256 (14.1) Moderately severe 109 (6.0) Severe 51 (2.8) ElMs, n (%) 186 (10.2) Any treatment since UC diagnosis, n (%) 1724 (94.9) Response to current UC treatment, n (%) Not applicable/no current treatment 63 (3.5) Too early to assess 187 (10.3) Complete response 757 (41.7)	None-minimal	822 (45.3)
Moderately severe 109 (6.0) Severe 51 (2.8) ElMs, n (%) 186 (10.2) Any treatment since UC diagnosis, n (%) 1724 (94.9) Response to current UC treatment, n (%) Not applicable/no current treatment 63 (3.5) Too early to assess 187 (10.3)	Mild	556 (30.6)
Severe 51 (2.8) EIMs, n (%) 186 (10.2) Any treatment since UC diagnosis, n (%) 1724 (94.9) Response to current UC treatment, n (%) Not applicable/no current treatment 63 (3.5) Too early to assess 187 (10.3)	Moderate	256 (14.1)
EIMs, n (%) Any treatment since UC diagnosis, n (%) Response to current UC treatment, n (%) Not applicable/no current treatment Too early to assess 187 (10.3)	Moderately severe	109 (6.0)
Any treatment since UC diagnosis, n (%)1724 (94.9)Response to current UC treatment, n (%)63 (3.5)Not applicable/no current treatment63 (3.5)Too early to assess187 (10.3)	Severe	51 (2.8)
Response to current UC treatment, n (%)Not applicable/no current treatment63 (3.5)Too early to assess187 (10.3)	ElMs, n (%)	186 (10.2)
Not applicable/no current treatment 63 (3.5) Too early to assess 187 (10.3)	Any treatment since UC diagnosis, n (%)	1724 (94.9)
Too early to assess 187 (10.3)	Response to current UC treatment, n (%)	
,	Not applicable/no current treatment	63 (3.5)
Complete response 757 (41.7)	Too early to assess	187 (10.3)
	Complete response	757 (41.7)

^{*} Only available observed data are shown.

Results

Partial response

No response

BL demographic & clinical characteristics of 1816 UC pts enrolled in ICONIC are summarized in Table 1. At BL, pt/physician PRISM was moderately correlated with SIBDQ, PHQ-9, P-SCCAI, or SCCAI (Table 2). For 1796 pts with self & physician assessments, most showed agreement on disease severity (concordant pairs: mild 60.3%, moderate 60.6%, severe 56.0%) (κ =0.43, 95% CI 0.40–0.47, P<0.0001). Although P-SCCAI & physician SCCAI mean values±SD differed (4.2±3.6 & 3.0±3.0 [P<0.0001]), the measures were highly correlated (Table 2). For pt/physician PRISM assessments, mean scores (4.0±2.5 & 4.3±2.4, respectively) differed (P<0.0001) & were moderately correlated (Table 2).

712 (39.2)

70 (3.9)



